DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Wegovy - 2 Debeka - 2 Robert Koch - 2 Ludwig Burger - 2 Maggie Fick - 2 Doctor Thomas Horbach - 1 Novo - 1 Jessica Lenth - 1
Top related locs:
Germany United States Norway Denmark Danish Wegovy Frankfurt London
Top related orgs:
Novo Nordisk - 2 Novo - 2 Allianz - 2 European Union - 2 Robert Koch Institute - 2 Thomson - 2 LVMH - 1 FRANKFURT - 1

Search resuls for: "Debeka"


2 mentions found


☆ Novo Nordisk weight-loss drug Wegovy launched in Germany, first big EU market
  + stars: | 2023-07-29 | by ( Ludwig Burger Maggie Fick | Ludwig Burger | Maggie Fick | ) www.reuters.com   time to read: +3 min
FRANKFURT, July 29 (Reuters) - Novo Nordisk has launched blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros out of pocket for a drug that public health insurance plans are so far barred from covering. The Danish drugmaker's share price has more than doubled in the two years since the drug debuted, turning Novo (NOVOb.CO) into Europe's second-most-valuable listed company after LVMH. Among major providers, Allianz (ALVG.DE) says it will pay if a physician diagnoses a medical need, while Debeka said its plans exclude weight-loss treatments. Novo is ramping up production to meet soaring demand in the United States, where the drug sells for as much as $1,350 a month. Doctors say many Germans seeking to lose weight have already used Ozempic, a diabetes drug also made by Novo that is a lower dose version of the same ingredient as Wegovy.
Persons: Wegovy, Debeka, Robert Koch, Ludwig Burger, Maggie Fick Organizations: Novo Nordisk, Novo, LVMH, Allianz, European Union, Robert Koch Institute, Thomson Locations: FRANKFURT, Germany, United States, Europe, Norway, Denmark, Danish, Novo, Wegovy, Frankfurt, London
☆ "Last hope": Eager Germans are prepared to pay for weight-loss drug
  + stars: | 2023-07-25 | by ( Ludwig Burger Maggie Fick | Ludwig Burger | Maggie Fick | ) www.reuters.com   time to read: +8 min
Interviews with seven doctors and two other potential users of Wegovy from Germany, where Novo Nordisk's (NOVOb.CO) weight-loss drug will become available at the end of July, show the office administrator isn't alone. Allianz (ALVG.DE) says it will pay if a physician diagnoses a medical need while Debeka said its plans exclude weight-loss treatments. In Germany, Wegovy will be administered with the same injection pen used in Norway and Denmark, not the one used in the United States to avoid hitting supplies there. "Patients are so desperate in Germany that they will pay out of their pocket for the medication." "My experience is that people will be able to pay for it out of (their own) pocket," said Horbach.
Persons: Doctor Thomas Horbach, Wegovy, Novo, Jessica Lenth, isn't, I've, Lenth, Debeka, Robert Koch, Danish drugmaker, Sylvia Weiner, Karl Rheinwalt, Thomas Horbach, Weiner, Rheinwalt, Juergen Ordemann, Michael Wirtz, Wirtz, Irina Ernstberger, Ernstberger, Ludwig Burger, Maggie Fick, Patricia Weiss, Josephine Mason, Catherine Evans Organizations: Novo Nordisk, FRANKFURT, Reuters, Allianz, European Union, Robert Koch Institute, Sana Klinikum, St, Hospital, Ozempic, Novo, Thomson Locations: Germany, Munich, LONDON, Hamburg, Wegovy, United States, Danish, Norway, Denmark, Sana, Frankfurt, St Franziskus, Hospital Cologne, Berlin's, Winsen, Lower Saxony, London
0 next >>
Total: 2